Changes of doxorubicin distribution in blood and plasma after its inclusion into nanophospholipd formulation

   


1. Institute of Biomedical Chemistry, Russian Academy of Sciences
Type: Experimental/clinical study
DOI: 10.18097/pbmc20115702174      UDK: 576.3.3144; 616.36002; 615.2.244      PubMed Id: 21870602
Year: 2011 vol: 57  issue:2  pages: 174-179
Abstract: The drug composition based on the plant phospholipids and the antitumor drug doxorubicin (particle size <30 nm) was obtained using original technology elaborated in the Institute of Biomedical Chemistry (Russian Academy of Medical Sciences). In in vitro experiments demonstrated decreased drug association with blood cells for this nanophospholipid form as compared with free doxorubicin. This was accompanied by a with corresponding increase in its plasma level ans also by drug redistribution from plasma protein fraction to high density lipoproteins. Significance of these changes for doxorubicin biodistributon and antitumor activity is discussed.
Download PDF:
Reference: Zykova M.G., Ipatova O.M., Prozorovskiy V.N., Medvedeva N.V., Voskresenskaya A.A., Zakharova T.S., Torkhovskaya T.I., Changes of doxorubicin distribution in blood and plasma after its inclusion into nanophospholipd formulation, Biomeditsinskaya khimiya, 2011, vol: 57(2), 174-179.
This paper is also available as the English translation:10.1134/S1990750812010155
Bibliography
 2016(Vol:62)
 2015(Vol:61)
 2014(Vol:60)
 2013(Vol:59)
 2012(Vol:58)
 2011(Vol:57)
 2010(Vol:56)
 2009(Vol:55)
 2008(Vol:54)
 2007(Vol:53)
 2006(Vol:52)
 2005(Vol:51)
 2004(Vol:50)
 2003(Vol:49)